Tenaya Therapeutics’ (TNYA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a research report sent to investors on Wednesday,Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Other equities research analysts have also recently issued reports about the stock. Piper Sandler restated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and issued a $16.00 price target on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research note on Wednesday. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Tenaya Therapeutics currently has an average rating of “Buy” and a consensus target price of $17.33.

Tenaya Therapeutics Price Performance

Shares of NASDAQ:TNYA opened at $1.67 on Wednesday. The firm has a market capitalization of $132.30 million, a price-to-earnings ratio of -1.16 and a beta of 2.72. The business’s 50 day simple moving average is $2.43 and its 200-day simple moving average is $2.69. Tenaya Therapeutics has a 12 month low of $0.99 and a 12 month high of $7.01.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.07. On average, equities analysts anticipate that Tenaya Therapeutics will post -1.35 earnings per share for the current year.

Hedge Funds Weigh In On Tenaya Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Synovus Financial Corp acquired a new position in Tenaya Therapeutics in the 3rd quarter valued at $28,000. Geode Capital Management LLC grew its position in shares of Tenaya Therapeutics by 5.4% in the third quarter. Geode Capital Management LLC now owns 1,296,156 shares of the company’s stock valued at $2,502,000 after purchasing an additional 66,968 shares during the period. XTX Topco Ltd grew its position in shares of Tenaya Therapeutics by 51.2% in the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock valued at $95,000 after purchasing an additional 16,687 shares during the period. Wellington Management Group LLP increased its stake in Tenaya Therapeutics by 35.6% in the third quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock valued at $568,000 after purchasing an additional 77,235 shares during the last quarter. Finally, State Street Corp lifted its position in Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after buying an additional 9,506 shares during the period. Hedge funds and other institutional investors own 90.54% of the company’s stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.